Breaking down the costs of treating nAMD: Biosimilar ranibizumab offers hope

The development of biosimilars has become an increasingly important aspect of the pharmaceutical industry in recent years, as these drugs offer an opportunity to provide more affordable treatment options to patients without compromising on efficacy or safety. According to BioIntel360, the global biosimilars market is expected to grow from $15.67 billion in 2021 to $19.10 billion in 2022 at a compound annual growth rate (CAGR) of 21.8%. The biosimilars market is expected to reach $42.30 billion in 2026 at a CAGR of 22%. One recent study has demonstrated the effectiveness of a biosimilar version of the drug ranibizumab in treating neovascular age-related macular degeneration (nAMD), a condition that can cause severe vision loss in older adults. Anticipated to affect a growing number of people due to the ageing of populations in many nations, neovascular age-related macular degeneration (nAMD) is one of the most prevalent causes of blindness worldwide, impacting over 200 million individuals.

Ranibizumab, a humanized antibody fragment, is an effective anti-vascular endothelial growth factor (VEGF) drug used to treat neovascular age-related macular degeneration (nAMD). It targets all VEGF-A isoforms and prevents VEGF molecules from binding to their receptors, as shown in the MARINA and ANCHOR phase III clinical trials, leading to its FDA approval in 2006.
In the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA) trial, 716 patients with nAMD were randomly assigned to receive either ranibizumab 0.3 mg, ranibizumab 0.5 mg, or a sham intravitreal injection.

However, due to the chronic nature of nAMD and the short half-life of the drug, patients must endure a significant burden of expense, monthly clinic visits, and injections. Moreover, real-world research indicates that the visual benefits are inferior to those observed in randomized controlled clinical trials. Inadequate adherence to treatment regimens and fewer injections leads to vision loss over time.

The innovator drug, marketed under the brand name Lucentis, is highly effective in slowing the progression of nAMD and improving patients’ vision. However, Lucentis can be quite expensive, making it difficult for many patients to access.

In recent years, several biosimilar versions of ranibizumab have been developed and approved for use in Europe, including Razumab, RapiSCE, and RAZUMABU. These biosimilars are highly similar to Lucentis in terms of their structure, efficacy, and safety profile.
In a study published in the British Journal of Ophthalmology, researchers compared the efficacy and safety of Razumab, a biosimilar version of ranibizumab, to Lucentis in the treatment of nAMD. The study included 120 patients who were randomly assigned to receive either Razumab or Lucentis.
After 12 months of treatment, the researchers found that both drugs were equally effective in improving patients’ vision and slowing the progression of nAMD. Patients in both groups experienced similar improvements in visual acuity, and there were no significant differences in the rates of adverse events between the two groups.
These findings are encouraging, as they suggest that biosimilar versions of ranibizumab can provide similar benefits to patients as the innovator drug, while potentially reducing the cost of treatment. This is particularly important given the high prevalence of nAMD in older adults, many of whom may struggle to afford the high cost of Lucentis treatment.

Of course, it is important to note that this study only looked at one specific biosimilar version of ranibizumab, and more research will be needed to fully assess the efficacy and safety of other biosimilar versions. However, these findings provide a promising starting point for further investigation into the use of biosimilars in the treatment of nAMD.

The future of biosimilars in the treatment of neovascular age-related macular degeneration (nAMD) looks promising, with the potential to improve patient access to effective treatment while reducing costs. As more biosimilars become available and are approved for use, patients and healthcare providers may have more options to choose from, allowing for greater flexibility in treatment planning. Additionally, ongoing research into the efficacy and safety of biosimilars in the treatment of nAMD and other conditions will continue to evolve clinical practice and improve patient outcomes. Overall, the development and use of biosimilars represents an important step forward in the effort to provide affordable, effective treatment options for patients with nAMD and other chronic conditions.

BioIntel360 anticipates that the development of biosimilar versions of ranibizumab has the potential to improve access to effective treatment for nAMD, while reducing the financial burden on patients and healthcare systems. This study adds to the growing body of evidence supporting the use of biosimilars in the treatment of a variety of conditions, and highlights the importance of continued research in this area.